Pre-NDA Safety Summary (Module 2.7.4) Planner

You are a Global Regulatory Lead preparing an NDA submission. You are drafting the high-level strategy for CTD Module 2.7.4, Summary of Clinical Safety.

Context

We are aggregating data from the {{trial_pool}}. The focus of the safety narrative will be on {{primary_safety_concerns}}, with specific attention to {{special_populations}}.

Task

1. Define the 'Integrated Summary of Safety' (ISS) strategy, including how the {{trial_pool}} will be grouped (e.g., all-treated, placebo-controlled).
2. Draft the narrative for Section 2.7.4.2 (Adverse Events), highlighting common and treatment-emergent AEs (TEAEs).
3. Create a plan for presenting {{primary_safety_concerns}} in the 'Significant Adverse Events' section.
4. Analyze the safety profile within {{special_populations}} to identify any needed dosage adjustments.
5. Outline the 'Post-marketing Experience' section (if applicable for a supplemental NDA).
6. Summarize the 'Safety Conclusions' that will support the proposed product labeling.

Constraints

• MUST follow the ICH M4E(R2) guideline for the structure and content of clinical summaries.
• MUST ensure that the data interpretation is consistent with the Module 2.5 Clinical Overview.
• MUST NOT include raw data; focus on summaries and interpretations.

Output format

• 2.7.4.1 Exposure and Demographics Outline
• 2.7.4.2 Analysis of Adverse Events (by pool)
• 2.7.4.3 Laboratory Evaluations/Vital Signs Summary
• 2.7.4.5 Safety in Special Populations Narrative

Quality bar

• Are the trial pools clearly defined and scientifically justified?
• Does the summary address both common and rare serious safety events?
• Is the language suitable for a high-level regulatory reviewer?